Psychiatry/Psychology | New Developments

Kures

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

ATAI Life Sciences Takes on Opioid Crisis by Acquiring Kures to Develop Novel Therapeutics for Opioid Abuse

Lead Product(s): KUR-101

Therapeutic Area: Psychiatry/Psychology Product Name: KUR-101

Highest Development Status: Undisclosed Product Type: Small molecule

Partner/Sponsor/Collaborator: ATAI Life Sciences

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Acquisition July 09, 2020

Details:

Kures' flagship product, KUR-101, is a derivative of mitragynine, the major active alkaloid of the kratom plant. KUR-101 will join ATAI's pipeline of ground-breaking mental health interventions such as arketamine and psilocybin.

OWP Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

OWP Pharmaceuticals Announces Patent Application for the First-Ever Powder for Oral Liquid Formulation of Duloxetine Hydrochloride for Major...

Lead Product(s): Duloxetine Hydrochloride

Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 08, 2020

Details:

Duloxetine hydrochloride is a serotonin and norepinephrine reuptake inhibitor (SNRI) and the delayed-release capsules, for oral use, were first approved in the U.S. in 2004.

IntelGenx

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Cybin Corp. and IntelGenx Corp. Enter Into Feasibility Agreement for Fast-Acting, Orally-Dissolving Psilocybin Film

Lead Product(s): Psilocybine

Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Small molecule

Partner/Sponsor/Collaborator: Cybin Corp

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement July 07, 2020

Details:

Cybin has entered into a feasibility agreement with IntelGenx Corp for the development of an orally-dissolving film for the delivery of pharmaceutical-grade psilocybin, subject to receipt of all necessary regulatory approvals.

NeuroPharma

Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Mydecine Innovations Group to Acquire NeuroPharm Inc.

Lead Product(s): Psilocybine

Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Small molecule

Partner/Sponsor/Collaborator: Mydecine

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Acquisition June 10, 2020

Details:

Mydecine and NeuroPharm will combine to focus on an integrated health and wellness research strategy and the development of products underpinned by therapies to assist veterans with mental health issues.

Katana Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Katana Pharmaceuticals Gets $1.05 M Grant to Support the Development of a Novel Non-Opioid Treatment for Neonatal Abstinence Syndrome

Lead Product(s): Non-opioid drug

Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Undisclosed

Partner/Sponsor/Collaborator: March of Dimes

Deal Size: $1.1 million Upfront Cash: Undisclosed

Deal Type: Funding June 04, 2020

Details:

The current Innovative Challenge Grant allows Katana Pharmaceutical to develop a novel non-opioid treatment for neonatal abstinence syndrome (NAS).

Delos Psyche Research Group

Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

New Wave Holdings Corp Provides Funding for LSD Research Study

Lead Product(s): Lysergide

Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Small molecule

Partner/Sponsor/Collaborator: New Wave Holdings Corp

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Funding June 04, 2020

Details:

Funding will support the Delos Psyche Research Group in its study designed to determine the impact of ingesting small amounts of hallucinogenic or psychedelic substances such as lysergic acid diethylamide for medicinal or therapeutic purposes.

University Hospital Basel

Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

MindMed Adds MDMA to Develop Next-Gen Psychedelic Therapies

Lead Product(s): Methylenedioxymethamphetamine

Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Small molecule

Partner/Sponsor/Collaborator: Mind Medicine

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Expanded Collaboration May 27, 2020

Details:

MindMed has committed to fund future R&D of new psychedelic therapies being pursued by the Liechti Lab with the intention to create next-gen psychedelic inspired medicines that incorporate MDMA as a component of these therapies.

National Institute on Drug Abuse

Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

CaaMTech Collaborates With National Institutes of Health to Research Psychedelics

Lead Product(s): Psilocybine

Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Small molecule

Partner/Sponsor/Collaborator: CaaMTech

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement May 07, 2020

Details:

The Designer Drug Research Unit at the National Institute on Drug Abuse will conduct research on CaaMTech's library of tryptamine-based compounds.

VistaGen Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

VistaGen Expands PH94B Clinical Development to Include Adjustment Disorder Related to COVID-19

Lead Product(s): PH94B

Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 28, 2020

Details:

VistaGen plans to submit its proposed protocol for a Phase 2 study of PH94B for treatment of adjustment disorder to the U.S. FDA through the FDA's new Coronavirus Treatment Acceleration Program.

CB Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

CB Therapeutics Enters into Collaboration Agreement with Cleveland Clinic for the Manufacture of Psilocybin

Lead Product(s): Psilocybine

Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Small molecule

Partner/Sponsor/Collaborator: Cleveland Clinic

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration April 20, 2020

Details:

The MOU singed between the companies include, production of psilocybin and like molecules used in combination with psychotherapy for the treatment of depression and addiction, and two other molecule.

Find

Find Novel Psychiatry/Psychology Drugs in Clinical Development

Undisclosed

Product Type

Companies

Kures

ATAI Life Sciences Takes on Opioid Crisis by Acquiring Kures to Develop Novel Therapeutics for Opioid Abuse

OWP Pharmaceuticals

OWP Pharmaceuticals Announces Patent Application for the First-Ever Powder for Oral Liquid Formulation of Duloxetine Hydrochloride for Major...

IntelGenx

Cybin Corp. and IntelGenx Corp. Enter Into Feasibility Agreement for Fast-Acting, Orally-Dissolving Psilocybin Film

NeuroPharma

Mydecine Innovations Group to Acquire NeuroPharm Inc.

Katana Pharmaceuticals

Katana Pharmaceuticals Gets $1.05 M Grant to Support the Development of a Novel Non-Opioid Treatment for Neonatal Abstinence Syndrome

Delos Psyche Research Group

New Wave Holdings Corp Provides Funding for LSD Research Study

University Hospital Basel

MindMed Adds MDMA to Develop Next-Gen Psychedelic Therapies

National Institute on Drug Abuse

CaaMTech Collaborates With National Institutes of Health to Research Psychedelics

VistaGen Therapeutics

VistaGen Expands PH94B Clinical Development to Include Adjustment Disorder Related to COVID-19

CB Therapeutics

CB Therapeutics Enters into Collaboration Agreement with Cleveland Clinic for the Manufacture of Psilocybin